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Abstract
Background: Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is a rare lethal lung
developmental disorder caused by heterozygous point mutations or genomic deletions involving FOXF1 or its
60-kb tissue-specific enhancer region mapping 270 kb upstream of FOXF1 and involving fetal lung-expressed
long non-coding RNA genes and CpG-enriched sites. Recently, we have proposed that the FOXF1 locus at
16q24.1 may be a subject of genomic imprinting.
Findings: Using custom-designed aCGH and Sanger sequencing, we have identified a novel de novo 104 kb
genomic deletion upstream of FOXF1 in a patient with histopathologically verified full phenotype of ACDMPV.
This deletion allowed us to further narrow the FOXF1 enhancer region and identify its critical 15-kb core
interval, essential for lung development. This interval harbors binding sites for lung-expressed transcription
factors, including GATA3, ESR1, and YY1, and is flanked by the lncRNA genes and CpG islands. Bisulfite
sequencing of one of these CpG islands on the non-deleted allele showed that it is predominantly
methylated on the maternal chromosome 16.
Conclusions: Substantial narrowing and bisulfite sequencing of the FOXF1 enhancer region on 16q24.1
provided new insights into its regulatory function and genomic imprinting.
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Introduction
Alveolar capillary dysplasia with misalignment of
pulmonary veins (ACDMPV, MIM 265380) is a lethal
neonatal developmental lung disorder characterized by re-
duced number of pulmonary capillaries, muscular thicken-
ing in small pulmonary arterioles, and abnormally situated
pulmonary veins running alongside pulmonary arterioles
[1, 2]. Patients with ACDMPV present with respiratory dis-
tress usually accompanied by pulmonary hypertension and
often by extra-pulmonary anomalies [3, 4].
In the vast majority of patients with ACDMPV, heterozy-
gous de novo point mutations or genomic deletion copy-
number variants (CNVs) of FOXF1 or its distant enhancer
region on chromosome 16q24.1 have been identified [4–7].
FOXF1 is a transcription factor involved, among others,
in maintaining the endothelial barrier through activation
of the S1P/S1PR1 signaling required for the integrity of
adherens junctions [8].
An ~60 kb distant tissue-specific enhancer region
(chr16:86,212,040-86,271,919; hg19) located 270 kb up-
stream of FOXF1 has been defined following alignment of
ACDMPV causative deletion CNVs that did not include
FOXF1 [7]. This region encodes fetal lung-expressed long
non-coding RNAs, LINC01081 and LINC01082, and en-
compasses binding sites for numerous transcriptional reg-
ulators, including CEBP/p300, CTCF, and GLI2 [4, 7].
Both LINC01081 and GLI2 have been shown to positively
control FOXF1 expression in human fetal lung fibroblasts
[7, 9]. Recently, in vivo studies of the mouse syntenic re-
gion have shown that it likewise harbors a Foxf1 enhancer
[10]. Of note, 30 of 31 genomic deletions pathogenic for
ACDMPV, for which parental origin was determined,
occurred de novo on the maternal chromosome 16,
suggesting genomic imprinting of the FOXF1 locus [4].
Importantly, some of the GLI2-binding sites located
in the enhancer region have been found to reside in a
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partially methylated CpG island, and their function has
been shown to be methylation sensitive [7]. Moreover, the
putative promoter region of the LINC01081 gene also in-
cludes a CpG island that could potentially be involved in
its epigenetic regulation.
Here, we present a patient (144.3) manifesting full
phenotype of ACDMPV caused by a deletion CNV in-
volving only a portion of the 60-kb enhancer region that
enabled us to identify its critical 15-kb core interval.
Patient
The patient was a full-term baby boy, appropriate for
gestational age, born via normal spontaneous vaginal
delivery with meconium-stained amniotic fluid to a 22-
year-old, G2, P2 mother. Pregnancy was uncomplicated.
The mother had prenatal care and denied use of tobacco,
alcohol, or drugs. Neonatal resuscitation was routine.
Birth weight was 3.6 kg. Apgar scores were 8 and 9 at 1
and 5 min of life, respectively.
The patient’s early neonatal course was unremarkable
until approximately 8 h of life, when he developed re-
spiratory distress associated with oxygen saturations in
the 80’s on room air, prompting admission to the neo-
natal intensive care unit (NICU). Chest X-ray revealed
small bilateral pneumothoraxes and was not consistent
with meconium aspiration syndrome. Echocardiogram
showed patent foramen ovale with moderate right to left
shunting, small patent ductus arteriosus with little flow
into the pulmonary artery, mildly dilated right ventricle,
mildly dilated right atrium, and severe pulmonary hyper-
tension (3/4 systemic) while on inhaled nitric oxide
(iNO) via nasal cannula at 12 h of life.
Upon admission to the NICU, the patient was started
on iNO, initially via high flow nasal cannula without
significant improvement prompting intubation and
mechanical ventilation, first conventional followed by
high-frequency oscillatory ventilation (HFOV) at approxi-
mately 24 h of life. The patient was transferred to HFOV
plus iNO because of worsening hypoxemia complicated
by systemic hypotension. Follow-up CXR showed well-
expanded lungs and resolution of bilateral pneumotho-
raxes. The patient did not show significant improvement
despite good alveolar recruitment on HFOV, optimization
of systemic blood pressure with vasopressor medication,
and iNO therapy. At approximately 48 h of life, he
was placed on VV extracorporeal membrane oxygenation
(ECMO) due to refractory hypoxemic respiratory failure.
He remained relatively stable for 4 days on ECMO until
he developed a right pneumothorax, which required chest
tube placement. On day 7 of the ECMO run, the patient
developed a left pneumothorax complicated by large he-
mothorax, pulmonary hemorrhage, disseminated intravas-
cular coagulation, and tamponade physiology, including
severe metabolic/lactic acidosis despite maximal ECMO
and vasopressor support. On day 8 of the ECMO run, day
10 of life, the family decided to withdraw support given the
patient’s severe clinical deterioration and grim prognosis.
Histopathological evaluation at autopsy confirmed the
diagnosis of ACDMPV. The major pathological findings
in the lungs included congested pulmonary veins adjacent
to pulmonary arteries, thickened alveolar septae with
decreased numbers of centrally located capillaries, and
arteriolar hypertrophy of lungs.
Material and methods
DNA isolation and sequencing
Blood and FFPE lung samples were obtained after in-
formed consent. DNA had been extracted from peripheral
blood using Gentra Purgene Kit (Qiagen, Germantown,
MD) and from lung tissue using DNaesy Blood & Tissue
Kit (Qiagen). PCR products were treated with ExoSAP-IT
(USB, Cleveland, OH) and directly sequenced by the
Sanger method. Reference sequences were downloaded
from the UCSC Genome Browser (NCBI build 37/hg19,
http://genome.ucsc.edu). Sequences were assembled using
Sequencher v4.8 (Gene Codes, Ann Arbor, MI).
Array CGH and deletion analysis
Array CGH was done using custom-design 16q24.1
region-specific 4 × 180 K microarrays (Agilent, Santa Clara,
CA) according to manufacturer protocol. Deletion junc-
tions were amplified using LA Taq polymerase (Takara
Bio., Madison, WI). Parental origin of the deletion-bearing
chromosome was determined following identification
of informative SNPs and microsatellite polymorphism
in a region of parental chromosome 16 corresponding
to patient’s deletion.
Bisulfite sequencing
Bisulfite modification of DNA was performed using the
EZ DNA Methylation-Lightning Kit (Zymo Research,
Irvine, CA). Human Methylated and Non-methylated
DNA Set (Zymo Research) was used to assess the effi-
ciency of bisulfite-mediated conversion of DNA. Primers
for PCR amplification of bisulfite-treated DNA (updelF:
5′-TTAGTTGGGGTTTATAAATTAGGTATTG-3′ and
updelR1: 5′-AAACATTTCAAATAAATCTTTTAATT
CC-3′) were designed using a MethPrimer software
(http://urogene.org/methprimer/index1.html). PCR was
performed in a 25-μL reaction mixture containing 200 ng
of bisulfite-treated DNA, and 0.75 units of Taq polymerase
(Invitrogen, Carlsbad, CA), applying 30 cycles of the three-
step incubation for 30 s at 94 °C, 30 s at 55 °C, and 1 min
at 72 °C. The PCR product was purified from unincorpor-
ated primers and nucleotides using the MinElute PCR
Purification Kit (Qiagen), and T-vector cloned in DH5α
cells using the pGEM-T Easy Vector System (Promega,
Madison, WI). Plasmid minipreps were prepared from 12
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randomly selected transformant colonies using the QIA-
prep Spin Miniprep Kit (Qiagen) and Sanger sequenced
using SP6 universal primer.
Results
Sanger sequencing of the coding portion of FOXF1
did not reveal any single nucleotide or indel variant.
Array CGH identified a 104-kb heterozygous deletion
CNV upstream of FOXF1, partially overlapping the
60-kb enhancer region (Fig. 1). Sequencing of the
PCR-amplified deletion junction showed that the deletion
proximal breakpoint maps at chr16:86,149,407 within a
simple repeat (CATATA)n and the distal breakpoint maps
at chr16:86,253,509 within a unique sequence (Additional
Fig. 1 Schematic representation of a protein-coding gene desert-region on 16q24.1 containing the FOXF1 upstream enhancer. a ENCODE and
b RefSeq annotations of the region (GRCh37/hg19). c Delineation of the enhancer 15-kb critical interval (black frame) by array CGH. SRO ~60 kb
smallest deletion overlap (see Additional file 1: Figure S3)
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file 1: Figure S1). There was no microhomology at
the breakpoints. Parental studies revealed that the de-
letion arose on the maternal chromosome 16 (Additional
file 1: Table S1, Figure S2). We did not detect by PCR any
evidence of low-level somatic mosaicism in the parental
DNA samples from the peripheral blood, indicating that
the deletion arose de novo.
Comparison of the region deleted in the described
patient 144.3 with that deleted in patient 99.3 who was
diagnosed with a late onset ACDMPV (chr16:84,764,628-
86,238,601) [10] enabled us to define the 15-kb critical en-
hancer interval chr16:86,238,601-86,253,509. This interval
harbors sequences predicted by the encyclopedia of DNA
Elements (ENCODE) project to function as transcriptional
enhancer (Fig. 1a). It is characterized in the human lung
fibroblasts by increased DNase hypersensitivity, signifi-
cantly increased ratio of histone H3 Lys 4 mono-
methylation (H3K4Me1, a typical marker of active
transcriptional enhancers) compared with trimethyla-
tion (H3K4Ma3, typical for promoters), and the pres-
ence of histone acetylation H3K27Ac (typical for active
enhancers) (Fig. 1b). In addition to harboring the CTCF
binding sites, the identified 15-kb region contains also the
clustered binding sites for multiple transcription factors
expressed in the lung (BioGPS, http://biogps.org), includ-
ing GATA3, ESR1, GABPA, YY1, SMC3, RAD21, MYC,
MAX, and SPI1 that might explain its function as a posi-
tive regulator of transcription (Fig. 1b).
The 15-kb interval does not encompass clearly defined
CpG islands. However, it is possible that it harbors the
CpG island-free differential methylation region (DMR)
for the locus. Nonetheless, this region neighbors a par-
tially methylated CpG island overlapping the GLI2-
binding sites that have been shown previously to regu-
late in vitro expression of FOXF1 [7]. We have bisulfite
sequenced this CpG island in the lung DNA from pa-
tients 144.3 and 60.4 with the FOXF1 upstream enhancer
region deleted on the maternal chromosome 16 [7] from
two normal lung samples (Additional file 1: Figure S3).
Interestingly, we have found that although the methylation
of this CpG island is variable in the patient and normal
lungs, the extent of methylation depends on the parental
origin of chromosome 16 with 4 of 11 CpG sites analyzed
being preferentially methylated on the maternal allele
overlapping the GLI2-binding sites.
Discussion
Using customized region-specific high-resolution array
CGH, we have identified a functionally essential 15-kb
core interval in the FOXF1 upstream enhancer region.
In fetal lung fibroblasts, this interval features histone
modifications typically found in active enhancers and
contains sites for binding of numerous transcription fac-
tors. In addition to binding CTCF, which can mediate
long-range chromatin interactions, of note are the bind-
ing sites for GATA3, ESR1, and YY1. GATA3 is a pion-
eer transcription factor recruiting SWI/SNF chromatin
remodeling complex. It is essential for chromatin modi-
fication that makes it accessible for ESR1 and other tran-
scription factors [11]. Interestingly, ESR1 has been found
to be involved in fetal lung development [12] and medi-
ation of long-range chromatin looping that can position
enhancer-bound transcription factors in the proximity to
their target promoter [13]. YY1 is a multifunctional tran-
scription factor of the Polycomb family also required
during lung morphogenesis. It is expressed in lung mes-
enchyme [14] as well as in epithelium where it targets
SHH expression known to regulate FOXF1 expression.
The deletion in patient 144.3 occurred on maternal
chromosome 16, similarly to 30 of 31 other deletions
pathogenic for ACDMPV in this region [4] (Additional file
1: Figure S3), further indicating that the FOXF1 locus on
16q24.1 is imprinted. However, the 15-kb core interval
does not contain any well-defined CpG island, and other
chromatin modifications such as histone methylation or
acetylation can contribute to genomic imprinting of this
genomic region.
We have elected to bisulfite sequence the CpG island
overlapping the GLI2-binding sites located proximally to
the 15-kb interval that has been shown to be partially
methylated [7]. We found that the extent of methylation
of this CpG island was variable but overall higher on ma-
ternal chromosome 16, with four out of 11 CpG dinucleo-
tides being preferentially maternally methylated.
Interestingly, a small maternal DMR involving the Mcts2
retrogene mapping in an intron of the multi-exonic host
HM13 gene in mice has been shown to regulate HM13 ex-
pression in a parent-of-origin manner, demonstrating that
discrete regions can bring about imprinting [15]. This
finding supports a model of partial maternal imprinting of
the FOXF1 locus where loss of its paternal copy is embry-
onic lethal and loss of the maternal copy results in
ACDMPV [4]. However, most recently, no evidence of dif-
ferential methylation was found in the FOXF1 locus using
Illumina Infinium HumanMethylation450 BeadChip Array
analysis [16], indicating that other epigenetic mechanism
can be responsible for genomic imprinting of this locus.
The reported deletion does not include the lncRNA
LINC01081 gene, which we have shown to positively
regulate FOXF1 expression in vitro [10], suggesting that
LINC01081 may be less critically involved in FOXF1
regulation in developing lungs than previously thought.
Alternatively, the described 15-kb region may regulate
the expression of LINC01081 or some of its shorter iso-
forms (TCONS_00024760-3, TCONS_00025081, 2, 4, 5),
or eRNAs.
We conclude that the described 15-kb sequence located
between LINC01082 and LINC01081 encompasses the
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enhancer interval essential for regulation of the expression
of FOXF1 in the fetal lungs that functions likely as a scaf-
fold for transcription factors and mediator of chromatin
looping juxtaposing these factors, the FOXF1 promotor,
and/or the lncRNA genes. The putative imprinting center
for the FOXF1 locus on chromosome 16q24.1 may be
located either more centromeric (e.g., in the nearby CpG
island with GLI2-binding sites), telomeric (e.g., in the CpG
island overlapping with putative promoter of LINC01081),
or within this interval but not involving the CpG island. Al-
ternatively, mechanism(s) other than CpG methylation can
be responsible for the observed genomic imprinting. High-
resolution approaches, e.g., targeted DNA methylation ana-
lysis by next generation sequencing (methyl-Seq), can help
to unravel the molecular bases of this phenomenon.
Additional file
Additional file 1: Figure S1. Chromatopherogram of the sequence
across the 144.3 deletion junction. Note that GAA nucleotides inserted at
the junction of the deleted fragment (chr16:86,238,601-86,253,508). Table
S1. Determination of the maternal origin of the deletion upstream of
FOXF1 identified in the described ACDMPV patient 144.3. Figure S2.
Chromatopherograms of DNA sequences containing the informative
SNPs and microsatellite used to determine the parental origin of the
deletion in patient 144.3. Figure S3. Methylation status of the CpG island
mapping proximally to the 15 kb critical interval of the FOXF1 enhancer
region. Filled circles (chr16:86,232,414-86,232,582) represent methylated
CpGs. The inset shows average methylation status of each CpG. CpGs 1, 2, 6
and 11 are more often methylated on maternal chromosome 16. Figure S6.
Schematic representation of chromosome 16q24.1 deletions pathogenic for
ACDMPV. Thirty two of 33 deletion CNVs, which occurred on maternal
chromosome 16, are shown in red, the deletion on paternal chromosome is
shown in blue, and deletions, for which parental origin could not be
determined, are shown in black. Numbers refer to ACDMPV cases. Locations
of deletion breakpoints (BPs) are indicated by names of flanking repetitive
elements. SRO, smallest deletion overlap delineating upstream enhancer
region, unk unknown sequence, uniq unique sequence. Previously
published deletions are from the reference [4]. (DOCX 2158 kb)
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